Astonea Labs IPO Upcoming
Already have an account? Apply now
Schedule of Astonea Labs
| Issue open date | 27 May 2025 |
| Issue close date | 29 May 2025 |
| UPI mandate deadline | 29 May 2025 (5 PM) |
| Allotment finalization | 30 May 2025 |
| Refund initiation | 02 Jun 2025 |
| Share credit | 02 Jun 2025 |
| Listing date | 03 Jun 2025 |
| Mandate end date | 18 Jun 2025 |
| Lock-in end date for anchor investors (50%) | 29 Jun 2025 |
| Lock-in end date for anchor investors (remaining) | 28 Aug 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Astonea Labs
Astonea Labs, established in April 2017 and headquartered in Panchkula, Haryana, is a pharmaceutical and cosmeceutical manufacturing company. The company specializes in producing a diverse range of products, including antibiotics, antihistamines, antidiabetics, cardiovascular drugs, gynecological treatments, analgesics, antifungals, multivitamins, and various skincare, dental, and hair care items. Operating from a 7,500-square-meter facility, Astonea Labs adheres to stringent quality standards, holding certifications such as WHO-GMP, ISO 9001, ISO 22000, CE, PETA, HALAL, and ECO CERT. The company offers contract development and manufacturing (CDMO) services to both domestic and international clients, focusing on innovation and sustainable practices.
Financials of Astonea Labs
*All figures are in ₹ Crores.
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹37.67 crores |
| Fresh Issue | ₹37.67 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Working capital requirements | 19.75 (52%) |
| Capital expenditure requirement | 7.2 (19.11%) |
| Brand building | 4.95 (13.14%) |
| General corporate purposes | 5.77 (15.31%) |
Strengths
- Diverse product portfolio spanning pharmaceuticals and cosmeceuticals.
- State-of-the-art manufacturing facility with multiple quality certifications.
- Experienced management team with a focus on innovation.
- Growing presence in both domestic and international markets.
- Recent IPO to fund expansion and enhance production capabilities.
Risks
- Exposure to regulatory changes in the pharmaceutical industry.
- Dependence on third-party contracts for a significant portion of revenue.
- Competition from established players in the pharmaceutical and cosmetic sectors.
- Fluctuations in raw material prices are impacting production costs.
- Challenges in maintaining quality standards across diverse product lines.